ITCI - Intra-Cellular Therapies, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
New York,
United States
Type: Equity
ITCI price evolution
ITCI
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $149.52 | $101.15 | $144.01 | $77.48 |
| Short term investments | $350.17 | $393.62 | $370.6 | $462.98 |
| Net receivables | $114.02 | $102.67 | $95.96 | $81.55 |
| Inventory | $50.27 | $42.99 | $41.9 | $28.34 |
| Total current assets | $667.8 | $702.42 | $698.07 | $706.09 |
| Long term investments | ||||
| Property, plant & equipment | $14.58 | $15.15 | $15.44 | $15.98 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.5 | $15.24 | $15.53 | $16.06 |
| Total investments | $350.17 | $393.62 | $370.6 | $462.98 |
| Total assets | $728.29 | $717.66 | $713.6 | $722.16 |
| Current liabilities | ||||
| Accounts payable | $11.45 | $10.61 | $7.73 | $8.44 |
| Deferred revenue | ||||
| Short long term debt | $3.61 | $3.58 | $3.56 | $3.53 |
| Total current liabilities | $123.55 | $103.09 | $92.08 | $79.59 |
| Long term debt | $13.33 | $13.89 | $14.43 | $14.96 |
| Total noncurrent liabilities | $13.33 | $13.89 | $14.43 | $14.96 |
| Total debt | $16.94 | $17.48 | $17.99 | $18.49 |
| Total liabilities | $136.87 | $116.98 | $106.51 | $94.55 |
| Shareholders' equity | ||||
| Retained earnings | -$1617.16 | -$1588.58 | -$1564.32 | -$1521.54 |
| Other shareholder equity | $0.1 | -$1.33 | -$2.27 | -$2.7 |
| Total shareholder equity | $591.42 | $600.68 | $607.09 | $627.61 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $149.52 | $150.37 | $93.76 | $61.45 |
| Short term investments | $350.17 | $443.29 | $319.97 | $597.4 |
| Net receivables | $114.02 | $75.19 | $20.16 | $10.76 |
| Inventory | $50.27 | $23.92 | $7.95 | $7.06 |
| Total current assets | $667.8 | $737.96 | $467.28 | $690.9 |
| Long term investments | ||||
| Property, plant & equipment | $14.58 | $16.74 | $22.56 | $26.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.5 | $16.82 | $22.64 | $26.41 |
| Total investments | $350.17 | $443.29 | $319.97 | $597.4 |
| Total assets | $728.29 | $754.78 | $489.92 | $717.31 |
| Current liabilities | ||||
| Accounts payable | $11.45 | $10.39 | $8.69 | $5.5 |
| Deferred revenue | ||||
| Short long term debt | $3.61 | $4.57 | $6.73 | $5.54 |
| Total current liabilities | $123.55 | $83.24 | $53.36 | $36.85 |
| Long term debt | $13.33 | $15.47 | $18.67 | $23.6 |
| Total noncurrent liabilities | $13.33 | $15.47 | $18.67 | $23.6 |
| Total debt | $16.94 | $20.04 | $25.41 | $29.14 |
| Total liabilities | $136.87 | $98.71 | $72.03 | $60.45 |
| Shareholders' equity | ||||
| Retained earnings | -$1617.16 | -$1477.49 | -$1221.23 | -$937.1 |
| Other shareholder equity | $0.1 | -$4.19 | -$0.36 | $0.48 |
| Total shareholder equity | $591.42 | $656.07 | $417.89 | $656.86 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $132.1 | $126.17 | $110.79 | $95.31 |
| Cost of revenue | $10.7 | $9.13 | $7.16 | $6.75 |
| Gross Profit | $121.4 | $117.04 | $103.63 | $88.56 |
| Operating activities | ||||
| Research & development | $50.77 | $41.55 | $49.79 | $38.02 |
| Selling, general & administrative | $104.72 | $105.21 | $101.01 | $98.92 |
| Total operating expenses | $155.49 | $146.76 | $150.81 | $136.95 |
| Operating income | -$34.1 | -$29.71 | -$47.18 | -$48.39 |
| Income from continuing operations | ||||
| EBIT | -$28.13 | -$24.21 | -$42.65 | -$44.04 |
| Income tax expense | $0.45 | $0.04 | $0.14 | $0.01 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$28.58 | -$24.26 | -$42.78 | -$44.05 |
| Income (for common shares) | -$28.58 | -$24.26 | -$42.78 | -$44.05 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $464.37 | $250.31 | $83.8 | $22.81 |
| Cost of revenue | $33.74 | $20.44 | $8.03 | $1.9 |
| Gross Profit | $430.63 | $229.87 | $75.77 | $20.92 |
| Operating activities | ||||
| Research & development | $180.14 | $134.72 | $88.85 | $65.78 |
| Selling, general & administrative | $409.86 | $358.78 | $272.61 | $186.36 |
| Total operating expenses | $590.01 | $493.5 | $361.46 | $252.15 |
| Operating income | -$159.38 | -$263.63 | -$285.69 | -$231.23 |
| Income from continuing operations | ||||
| EBIT | -$139.04 | -$256.25 | -$284.12 | -$226.99 |
| Income tax expense | $0.64 | $0.01 | $0.01 | $0.01 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$139.67 | -$256.26 | -$284.13 | -$227.01 |
| Income (for common shares) | -$139.67 | -$256.26 | -$284.13 | -$227.01 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$28.58 | -$24.26 | -$42.78 | -$44.05 |
| Operating activities | ||||
| Depreciation | $0.14 | $0.14 | $0.12 | $0.13 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $14.88 | $14.34 | $13.25 | $10.46 |
| Total cash flows from operations | -$2.06 | -$25.27 | -$36.8 | -$60.07 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0.27 | ||
| Investments | $47.42 | -$19.9 | $94.75 | -$16.46 |
| Total cash flows from investing | $47.42 | -$20.17 | $94.75 | -$16.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3 | $2.58 | $8.59 | $3.64 |
| Net borrowings | ||||
| Total cash flows from financing | $3 | $2.58 | $8.59 | $3.64 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $48.37 | -$42.86 | $66.53 | -$72.89 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$139.67 | -$256.26 | -$284.13 | -$227.01 |
| Operating activities | ||||
| Depreciation | $0.53 | $0.66 | $0.53 | $0.53 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $52.92 | $43.1 | $34.48 | $24.33 |
| Total cash flows from operations | -$124.2 | -$270.19 | -$259.54 | -$230.07 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$0.78 | -$0.33 | -$0.27 |
| Investments | $105.81 | -$127.59 | $280.67 | -$480.03 |
| Total cash flows from investing | $105.54 | -$128.37 | $280.34 | -$480.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.81 | $455.16 | $11.52 | $664.18 |
| Net borrowings | ||||
| Total cash flows from financing | $17.81 | $455.16 | $11.52 | $664.18 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.85 | $56.6 | $32.32 | -$46.19 |
News
Fundamentals
| Market cap | $7.13B |
|---|---|
| Enterprise value | $7.00B |
| Shares outstanding | 96.38M |
| Revenue | $464.37M |
|---|---|
| EBITDA | -$138.51M |
| EBIT | -$139.04M |
| Net Income | -$139.67M |
| Revenue Q/Q | 50.34% |
| Revenue Y/Y | 85.51% |
| P/E ratio | -51.07 |
|---|---|
| EV/Sales | 15.08 |
| EV/EBITDA | -50.54 |
| EV/EBIT | -50.35 |
| P/S ratio | 15.36 |
| P/B ratio | 12.06 |
| Book/Share | 6.14 |
| Cash/Share | 1.55 |
| EPS | -$1.45 |
|---|---|
| ROA | -19.39% |
| ROE | -23.02% |
| Debt/Equity | 0.23 |
|---|---|
| Net debt/EBITDA | 0.09 |
| Current ratio | 5.41 |
| Quick ratio | 5.00 |